A single amino acid difference within the α-2 domain of two naturally occurring equine MHC class I molecules alters the recognition of Gag and Rev epitopes by equine infectious anemia virus-specific CTL

Journal of Immunology

Volumn 177, Issue 10, 2006, Pages 7377-7390

  Mealey, Robert H ^a   Lee, Jae Hyung ^b   Leib, Steven R ^a   Littke, Matt H ^a   McGuire, Travis C ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; REV PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ALLELE; ALPHA CHAIN; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CONFORMATIONAL TRANSITION; CYTOTOXIC T LYMPHOCYTE; EQUINE INFECTIOUS ANEMIA VIRUS; GENE EXPRESSION; GENE SEQUENCE; HORSE; IMMUNOGENETICS; LENTIVIRINAE; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 33750838981     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.10.7377     Document Type: Article

References (87)

1. Addo, M. M., M. Altfeld, E. S. Rosenberg, R. L. Eldridge, M. N. Philips, K. Habeeb, A. Khatri, C. Brander, G. K. Robbins, G. P. Mazzara, et al. The HIV-1 regulatory proteins tat and rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc. Natl. Acad. Sci. USA 98: 1781-1786.
2. Betts, M. R., J. F. Krowka, T. B. Kepler, M. Davidian, C. Christopherson, S. Kwok, L. Louie, J. Eron, H. Sheppard, and J. A. Frelinger. 1999. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. AIDS Res. Hum. Retroviruses 15: 1219-1228.
3. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol 68: 6103-6110.
4. + T cells in HIV-infected progressors and long-term nonprogressors. J. Immunol 165: 1082-1092.
5. Klein, M. R., C. A. Van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. Keet, J. K. Eeftinck Schattenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181: 1365-1372.
6. Goulder, P. J., M. A. Altfeld, E. S. Rosenberg, T. Nguyen, Y. Tang, R. L. Eldridge, M. M. Addo, S. He, J. S. Mukherjee, M. N. Phillips, et al. 2001. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193: 181-194.
7. Novitsky, V., P. Gilbert, T. Peter, M. F. McLane, S. Gaolekwe, N. Rybak, I. Thior, T. Ndung'u, R. Marlink, T. H. Lee, and M. Essex. 2003. Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J. Virol. 77: 882-890.
8. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279: 2103-2106.
9. Ogg, G. S., S. Kostense, M. R. Klein, S. Jurriaans, D. Hamann, A. J. McMichael, and F. Miedema. 1999. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression. J. Virol. 73: 9153-9160.
10. Rinaldo, C., X. L. Huang, Z. F. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, et al. 1995. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69: 5838-5842.
11. Gruters, R. A., C. A. van Baalen, and A. D. Osterhaus. 2002. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes. Vaccine 20: 2011-2015.
12. Van Baalen, C. A., O. Pontesilli, R. C. Huisman, A. M. Geretti, M. R. Klein, F. de Wolf, F. Miedema, R. A. Gruters, and A. D. Osterhaus. 1997. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78: 1913-1918.
13. Cheevers, W. P., and T. C. McGuire. 1985. Equine infectious anemia virus: immunopathogenesis and persistence. Rev. Infect. Dis. 7: 83-88.
14. McGuire, T. C., K. I. O'Rourke, and L. E. Ferryman. 1990. Immunopathogenesis of equine infectious anemia lemivirus disease. Dev. Biol. Stand. 72: 31-37.
15. Sellon, D. C., F. J. Fuller, and T. C. McGuire. 1994. The immunopathogenesis of equine infectious anemia virus. Virus Res. 32: 111-138.
16. Kono, Y., K. Hirasawa, Y. Fukunaga, and T. Taniguchi. 1976. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs. Natl. Inst. Anim. Health Q. Tokyo 16: 8-15.
17. + cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize env and gag/PR proteins. J. Virol. 68: 1459-1467.
18. McGuire, T. C., D. G. Fraser, and R. H. Mealey. 2002. Cytotoxic T lymphocytes and neutralizing antibody in the control of equine infectious anemia virus. Viral Immunol. 15: 521-531.
19. Mealey, R. H., D. G. Fraser, J. L. Oaks, G. H. Cantor, and T. C. McGuire. 2001. Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses. Clin. Immunol. 101: 237-247.
20. Mealey, R. H., S. R. Leib, S. L. Pownder, and T. C. McGuire. 2004. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection. J. Virol. 78: 9295-9305.
21. Perryman, L. E., K. I. O'Rourke, and T. C. McGuire. 1988. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 62: 3073-3076.
22. + T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses. J. Gen. Virol. 75: 959-968.
23. Hammond, S. A., S. J. Cook, D. L. Lichtenstein, C. J. Issel, and R. C. Montelaro. 1997. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J. Virol. 71: 3840-3852.
24. McGuire, T. C., W. Zhang, M. T. Hines, P. J. Henney, and K. M. Byrne. 1997. Frequency of memory cytotoxic T lymphocytes to equine infectious anemia virus proteins in blood from carrier horses. Virology 238: 85-93.
25. McGuire, T. C., S. R. Leib, S. M. Lonning, W. Zhang, K. M. Byrne, and R. H. Mealey. 2000. Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses. J. Gen. Virol. 81: 2735-2739.
26. Zhang, W., S. M. Lonning, and T. C. McGuire. 1998. Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J. Virol. 72: 9612-9620.
27. Mealey, R. H., B. Zhang, S. R. Leib, M. H. Littke, and T. C. McGuire. 2003. Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313: 537-552.
28. + lymphocytes in equine infectious anemia virus-infected horses using major histocompatibility complex class I/peptide tetrameric complexes. Virology 339: 110-126.
29. Chung, C., R. H. Mealey, and T. C. McGuire. 2004. CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in gag matrix and capsid proteins. Virology 327: 144-154.
30. Chung, C., R. H. Mealey, and T. C. McGuire. 2005. Evaluation of high functional avidity CTL to gag epitope clusters in EIAV carrier horses. Virology 342: 228-239.
31. Belshan, M., P. Baccam, J. L. Oaks, B. A. Sponseller, S. C. Murphy, J. Cornette, and S. Carpenter. 2001. Genetic and biological variation in equine infectious anemia virus rev correlates with variable stages of clinical disease in an experimentally infected pony. Virology 279: 185-200.
32. Leroux, C., C. J. Issel, and R. C. Montelaro. 1997. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J. Virol. 71: 9627-9639.
33. Germain, R. N., and D. H. Margulies. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11: 403-450.
34. Robinson, J., M. J. Waller, P. Parham, N. de Groot, R. Bontrop, L. J. Kennedy, P. Stoehr, and S. G. Marsh. 2003. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res. 31: 311-314.
35. Sette, A., and J. Sidney. 1998. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr. Opin. Immunol. 10: 478-482.
36. Sette, A., and J. Sidney. 1999. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50: 201-212.
37. Sidney, J., H. M. Grey, R. T. Kubo, and A. Sette. 1996. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today 17: 261-266.
38. Sidney, J., S. Southwood, and A. Sette. 2005. Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires. Immunogenetics 57: 393-408.
39. Muller, D., K. Pederson, R. Murray, and J. A. Frelinger. 1991. A single amino acid substitution in an MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes. J. Immunol. 147: 1392-1397.
40. Gao, X., G. W. Nelson, P. Karacki, M. P. Martin, J. Phair, R. Kaslow, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, et al. 2001. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344: 1668-1675.
41. +-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J. Virol. 76: 12603-12610.
42. Bailey, E. 1980. Identification and genetics of horse lymphocyte alloantigens. Immunogenetics 11: 499-506.
43. Bailey, E., E. Marti, D. G. Fraser, D. F. Antczak, and S. Lazary. 2000. Immunogenetics of the horse. In The Genetics of the Horse, A. T. Bowling and A. Ruvinsky, eds. CABI Publishing, New York.
44. Bernoco, D., D. F. Antczak, E. Bailey, K. Bell, R. W. Bull, G. Byrns, G. Guerin, S. Lazary, J. McClure, J. Templeton, et. al. 1987. Joint report of the Fourth International Workshop on lymphocyte alloantigens of the horse, Lexington, Kentucky, 12-22 October, 1985. Anim. Genet. 18: 81.
45. Lazary, S., D. F. Antczak, E. Bailey, T. K. Bell, D. Bernoco, G. Byrns, and J. J. McClure. 1988. Joint report of the Fifth International Workshop on lymphocyte alloantigens of the horse, Baton Rouge, Louisiana, 31 October-1 November 1987. Anim. Genet. 19: 447-456.
46. Barbis, D. P., J. K. Maher, J. Stanek, B. A. Klaunberg, and D. F. Antczak. 1994. Horse cDNA clones encoding two MHC class I genes. Immunogenetics 40: 163.
47. Carpenter, S., J. M. Baker, S. J. Bacon, T. Hopman, J. Maher, S. A. Ellis, and D. F. Antczak. 2001. Molecular and functional characterization of genes encoding horse MHC class I antigens. Immunogenetics 53: 802-809.
48. Chung, C., S. R. Leib, D. G. Fraser, S. A. Ellis, and T. C. McGuire. 2003. Novel classical MHC class I alleles identified in horses by sequencing clones of reverse transcription-PCR products. Eur. J. Immunogenet. 30: 387-396.
49. Ellis, S. A., A. J. Martin, E. C. Holmes, and W. I. Morrison. 1995. At least four MHC class I genes are transcribed in the horse: phylogenetic analysis suggests an unusual evolutionary history for the MHC in this species. Eur. J. Immunogenet. 22: 249-260.
50. Holmes, E. C., and S. A. Ellis. 1999. Evolutionary history of MHC class I genes in the mammalian order Perissodactyla. J. Mol. Evol. 49: 316-324.
51. McGuire, T. C., S. R. Leib, R. H. Mealey, D. G. Fraser, and D. J. Prieur. 2003. Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule. J. Immunol. 171: 1984-1993.
52. Tallmadge, R. L., T. L. Lear, and D. F. Antczak. 2005. Genomic characterization of MHC class 1 genes of the horse. Immunogenetics 57: 763-774.
53. Bailey, E. 1983. Population studies on the ELA system in American standardbred and thoroughbred mares. Anim. Blood Groups Biochem. Genet. 14: 201-211.
54. Terasaki, P. I., D. Bernoco, M. S. Park, G. Ozturk, and Y. Iwaki. 1978. Microdroplet testing for HLA-A, -B, -C, and -D antigens: The Phillip Levine Award Lecture. Am. J. Clin. Pathol. 69: 103-120.
55. Ellis, S. A., R. E. Bontrop, D. F. Antczak, K. Ballingall, C. J. Davies, J. Kaufman, L. J. Kennedy, J. Robinson, D. M. Smith, M. J. Stear, et al. 2006. ISAG/IUIS-VIC Comparative MHC Nomenclature Committee report, 2005. Immunogenetics 1-6.
56. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques 7: 980-982.
57. Lonning, S. M., W. Zhang, S. R. Leib, and T. C. McGuire. 1999. Detection and induction of equine infectious anemia virus-specific cytotoxic T-lymphocyte responses by use of recombinant retroviral vectors. J. Virol. 73: 2762-2769.
58. Shimizu, Y., D. E. Geraghty, B. H. Koller, H. T. Orr, and R. DeMars. 1988. Transfer and expression of three cloned human non-HLA-A,B,C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 85: 227-231.
59. Ridgely, S. L., and T. C. McGuire. 2002. Lipopeptide stimulation of MHC class I-restricted memory cytotoxic T lymphocytes from equine infectious anemia virus-infected horses. Vaccine 20: 1809-1819.
60. Ridgely, S. L., B. Zhang, and T. C. McGuire. 2003. Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge. Vaccine 21: 491-506.
61. Rivera, J. A., and T. C. McGuire. 2005. Equine infectious anemia virus-infected dendritic cells retain antigen presentation capability. Virology 335: 145-154.
62. Zhang, W., D. B. Auyong, J. L. Oaks, and T. C. McGuire. 1999. Natural variation of equine infectious anemia virus Gag protein cytotoxic T lymphocyte epitopes. Virology 261: 242-252.
63. Allen, T. M., D. H. O'Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat-specific cytotoxic T lymphocytes select for SFV escape variants during resolution of primary viraemia. Nature 407: 386-390.
64. Siliciano, R. F., A. D. Keegan, R. Z. Dintzis, H. M. Dintzis, and H. S. Shin. 1985. The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones. J. Immunol. 135: 906-914.
65. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184: 485-492.
66. Derby, M., M. Alexander-Miller, R. Tse, and J. Berzofsky. 2001. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166: 1690-1697.
67. del Guercio, M. F., J. Sidney, G. Hermanson, C. Perez, H. M. Grey, R. T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154: 685-693.
68. Greenwood, F. C., W. M. Hunter, and J. S. Glover. 1963. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem. J. 89: 114-123.
69. Marti-Renom, M. A., A. C. Stuart, A. Fiser, R. Sanchez, F. Melo, and A. Sali. 2000. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29: 291-325.
70. Miles, J. J., D. Elhassen, N. A. Borg, S. L. Silins, F. E. Tynan, J. M. Burrows, A. W. Purcell, L. Kjer-Nielsen, J. Rossjohn, S. R. Burrows, and J. McCluskey. 2005. CTL recognition of a bulged viral peptide involves biased TCR selection. J. Immunol. 175: 3826-3834.
71. Luthy, R., J. U. Bowie, and D. Eisenberg. 1992. Assessment of protein models with three-dimensional profiles. Nature 356: 83-85.
72. Canutescu, A. A., A. A. Shelenkov, and R. L. Dunbrack, Jr. 2003. A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci. 12: 2001-2014.
73. Tynan, F. E., N. A. Borg, J. J. Miles, T. Beddoe, D. El Hassen, S. L. Silins, W. J. van Zuylen, A. W. Purcell, L. Kjer-Nielsen, J. McCluskey, et al. 2005. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I: implications for T-cell receptor engagement and T-cell immunodominance. J. Biol. Chem. 280: 23900-23909.
74. Gabb, H. A., R. M. Jackson, and M. J. Sternberg. 1997. Modelling protein docking using shape complementarity, electrostatics and biochemical information. J. Mol. Biol. 272: 106-120.
75. Katchalski-Katzir, E., I. Shariv, M. Eisenstein, A. A. Friesem, C. Aflalo, and I. A. Vakser. 1992. Molecular surface recognition: determination of geometric fit between proteins and their ligands by correlation techniques. Proc. Natl. Acad. Sci. USA 89: 2195-2199.
76. Moont, G., H. A. Gabb, and M. J. Sternberg. 1999. Use of pair potentials across protein interfaces in screening predicted docked complexes. Proteins 35: 364-373.
77. Mancini, A. L., R. H. Higa, A. Oliveira, F. Dominiquini, P. R. Kuser, M. E. Yamagishi, R. C. Togawa, and G. Neshich. 2004. STING Contacts: a web-based application for identification and analysis of amino acid contacts within protein structure and across protein interfaces. Bioinformatics 20: 2145-2147.
78. Neshich, G., R. C. Togawa, A. L. Mancini, P. R. Kuser, M. E. Yamagishi, G. Pappas, Jr., W. V. Torres, T. Fonseca e Campos, L. L. Ferreira, F. M. Luna, et al. 2003. STING Millennium: a web-based suite of programs for comprehensive and simultaneous analysis of protein structure and sequence. Nucleic Acids Res. 31: 3386-3392.
79. Day, C. L., A. K. Shea, M. A. Altfeld, D. P. Olson, S. P. Buchbinder, F. M. Hecht, E. S. Rosenberg, B. D. Walker, and S. A. Kalams. 2001. Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles. J. Virol. 75: 6279-6291.
80. Moudgil, K. D., J. Wang, V. P. Yeung, and E. E. Sercarz. 1998. Heterogeneity of the T cell response to immunodominant determinants within hen eggwhite lysozyme of individual syngeneic hybrid F, mice: implications for autoimmunity and infection. J. Immunol. 161: 6046-6053.
81. Tynan, F. E., D. Elhassen, A. W. Purcell, J. M. Burrows, N. A. Borg, J. J. Miles, N. A. Williamson, K. J. Green, J. Tellam, L. Kjer-Nielsen, J. McCluskey, J. Rossjohn, and S. R. Burrows. 2005. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J. Exp. Med. 202: 1249-1260.
82. Shields, M. J., N. Assefi, W. Hodgson, E. J. Kim, and R. K. Ribaudo. 1998. Characterization of the interactions between MHC class I subunits: a systematic approach for the engineering of higher affinity variants of beta 2-microglobulin. J. Immunol. 160: 2297-2307.
83. Burrows, S. R., J. Rossjohn, and J. McCluskey. 2005. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol. 27: 11-16.
84. Green, K. J., J. J. Miles, J. Tellam, W. J. van Zuylen, G. Connolly, and S. R. Burrows. 2004. Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length. Eur. J. Immunol. 34: 2510-2519.
85. Bjorkman, P. J., M. A. Saper, B. Samraoui, W. S. Bennett, J. L. Strominger, and D. C. Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329: 506-512.
86. b. Science 257: 919-927.
87. Matsumura, M., D. H. Fremont, P. A. Peterson, and I. A. Wilson. 1992. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257: 927-934.